Crescent Capital has sold 14.3% of the float at $4.50, which could see the share price pull back to those levels. They still own 30.1% which comes out of escrow in Feb 2023. So likely to see selling pressure there.
But interestingly, if you get the 41c fully franked dividend in late August, you could get ACL for around $4.10. That's only slightly above IPO, but since then they paid down huge debt and made some acquisitions thanks to Covid testing. With pro format 44c EPS (normalising for covid), that's a PE of around 9; about a 5% fully franked dividend yield when NPAT normalises; and probably growth of 6-7%.
If you agree with the growth, it's cheap based on the Chowder rule (11-12% returns of dividend yield and EPS growth); still a bit expensive for Lynchs PEG ratio of 1.5.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$2.82 |
Change
-0.010(0.35%) |
Mkt cap ! $553.8M | |||
| Open | High | Low | Value | Volume |
| $2.83 | $2.83 | $2.78 | $1.879M | 670.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1071 | $2.80 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.83 | 2376 | 2 |
View Market Depth
| Last trade - 16.14pm 29/07/2025 (20 minute delay) ? |
| ACL (ASX) Chart |